STI-9199 / Sorrento - LARVOL DELTA

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sorrento Therapeutics, Inc. | N=24 ➔ 0 | Trial completion date: Oct 2022 ➔ Oct 2024 | Initiation date: Apr 2022 ➔ Apr 2023 | Completed ➔ Withdrawn | Trial primary completion date: Jun 2022 ➔ Jun 2024

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Sorrento Therapeutics, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Oct 2022

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Sorrento Therapeutics, Inc. | Not yet recruiting ➔ Active, not recruiting | N=700 ➔ 24 | Trial completion date: Jan 2023 ➔ Jul 2023 | Trial primary completion date: Jan 2023 ➔ Aug 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease